Clinical Trials Browser

Phase 2 × Neoplasms × balstilimab × Clear all

NCT06322108 2025-05-08

Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms